Downtown San Francisco
San Francisco — Amongst all the chaos and frenetic activity that abounds big Pharma at JPM each year, I always look forward to hearing what the smaller biotechs are up to on days 3 and 4, as well as seeing how far some of them have progressed since our previous update on their pipeline agents.
In this latest update, there are definitely some companies we have been following longitudinally who are either poised for future success and growth… or due for a correction if the promising science doesn’t pan out as expected in the clinic.
Indeed one of those companies has already hit success and disappointment in the last two months alone, such is the roller coaster that is oncology R&D.
Please note that this is a rolling blog, which means that numerous updates are added throughout the day as new information becomes available.
To learn more from our oncology coverage and get a heads up on our latest commentary JPM annual meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.
Dr Ira Mellman is a leading cancer researcher, familiar to many in cancer immunotherapy for his work on the Cancer-Immunity Cycle and Cancer-Immune Set-Point with Dr Dan Chen.
Prior to joining Genentech, he spent 20 years as a faculty member at Yale, publishing extensive research on dendritic cells.
River Rhine, Mainz
Last year, Genentech announced a strategic collaboration with Mainz based BioNTech in Germany to develop and manufacture personalized mRNA based cancer vaccines.
At the recent CRI-CIMT-EATI-AACR cancer international cancer immunotherapy conference in Mainz, Dr Mellman kindly spoke to BSB about the underlying biology/immunology, the rationale behind the BioNTech collaboration, and his vision on where he sees the potential for therapeutic cancer vaccines going forward.
This is the second post in our series on the Future of Cancer Vaccines.
Here’s a snippet of the interview with Dr Mellman to get you warmed up…
Subscribers can log-in to read our latest insights from ESMO17 or you can gain access to BSB Premium Content.